CN108659080A - A kind of 2`-C- methyl adenines nucleoside phosphoramidites monomer and its synthetic method - Google Patents

A kind of 2`-C- methyl adenines nucleoside phosphoramidites monomer and its synthetic method Download PDF

Info

Publication number
CN108659080A
CN108659080A CN201810535394.9A CN201810535394A CN108659080A CN 108659080 A CN108659080 A CN 108659080A CN 201810535394 A CN201810535394 A CN 201810535394A CN 108659080 A CN108659080 A CN 108659080A
Authority
CN
China
Prior art keywords
compound
formula
catalyst
nucleoside phosphoramidites
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201810535394.9A
Other languages
Chinese (zh)
Inventor
高元和
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nanjing Bai Fu Li Technology Co Ltd
Original Assignee
Nanjing Bai Fu Li Technology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanjing Bai Fu Li Technology Co Ltd filed Critical Nanjing Bai Fu Li Technology Co Ltd
Priority to CN201810535394.9A priority Critical patent/CN108659080A/en
Publication of CN108659080A publication Critical patent/CN108659080A/en
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16Purine radicals
    • C07H19/20Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C07H19/207Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids the phosphoric or polyphosphoric acids being esterified by a further hydroxylic compound, e.g. flavine adenine dinucleotide or nicotinamide-adenine dinucleotide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00Processes for the preparation of sugar derivatives
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention discloses a kind of 2'C methyl adenines nucleoside phosphoramidites monomer and its synthetic methods.The general structure of the compound is:The reaction step of the synthetic method of the 2'C methyl adenines nucleoside phosphoramidites monomer is as follows:

Description

A kind of 2`-C- methyl adenines nucleoside phosphoramidites monomer and its synthetic method
Technical field
The invention belongs to the chemosynthesis technical fields of nucleotide, more particularly to a kind of 2'-C- methyl adenines nucleosides Phosphoramidite monomer and its synthetic method.
Background technology
RNA perturbation techniques (RNA interference, RNAi) obtained Nobel's physiology and Medicine in 2006. RNA interference is the gene silencing phenomenon caused by double-stranded RNA on molecular biology, and mechanism is by hindering specific gene Translation or transcription carry out inhibition of gene expression.SiRNA (siRNA) is not only a kind of outstanding molecular biology research hand Section, it is often more important that, it is a kind of potential biomolecule with medicinal application foreground.In recent years, the medicinal application of siRNA As the research hotspot of scientific research institution and enterprise.The method of wherein chemical modification is a kind of very important means, although short Double stranded rna molecule can be used in gene silencing, and have higher activity and stability on a cellular level, but either It is all very necessary that an introducing modification or two chains, which all introduce modification, wherein.For medical application, into one It is highly important that step, which improves thermodynamic stability and the resistance of ribozyme,.Second, chemical modification can improve double-strand siRNA in body Internal half-life period.Third, chemical modification can also improve distribution and the pharmacokinetic properties of double-strand siRNA, and can allow SiRNA targets specific cell.4th, the affinity with target gene can be changed by suitable chemical modification, to carry The interference effect of high siRNA reduces the undershooting-effect of siRNA.2 '-O-Me and 2 '-F modifications are the siRNA modifications carried out earliest It explores, 2 '-O-Me and 2 '-F modifications are used interchangeably to modify natural siRNA can be to significantly improving its serum stable Property, and may can improve RNAi activity (Allerson, C. R. to a certain extent in partial sequence;Sioufi, N.; James, R., et al.J. Med. Chem, 2005,48,901.).SiRNA Synesis Company can provide both quotient at present The modification service of product.But it is chemical synthesis the development that highly difficult and cost limits chemical modification RNA technologies, more, more Complicated phosphoramidite monomer has to be developed.The selection of abundant chemical modification siRNA monomers will be promoted siRNA by the present invention The research and development of drug.
In recent years studies have shown that 2'-C- methyl adenine nucleosides shows up-and-coming anticancer drug, antiviral work Property and interested biochemical characteristic.(Ronald C. G.; Lillian Lou; Christopher D. R.; Uli Schmitz. Annual reports in medicinal chemistry, 2004, vol. 39, p. 223-237; Franchetti, P.; Cappellacci, L.; Marchetti, S.; Trincavelli, L.; Martini, C.; Mazzoni, M. R.; Lucacchini, A.; Grifantini, M.. J. Med. Chem., 1998, 41, 1708-1715; Matsuda, A.; Takenuki, K.; Sasaki,T.; Ueda, T. J. Med. Chem. 1991, 34, 234; Harry-O’Kuru, R. E.; Smith, J. M.; Wolfe, M. S. J. Org. Chem. 1997, 62, 1754; Awano, H.; Shuto, S.; Baba, M.; Kira, T.; Shigeta, S.; Matsuda, A. Bioorg. Med. Chem. Lett. 1994, 4, 367; Matsuda, A.; Azuma, A. Nucleosides Nucleotides 1995, 14, 461; Baker, C. H.; Banzon, J.; Bollinger, J. M.; Stubbe, J.; Samano,V.; Robin, M. J.; Lippert, B.; Jarvi, E.; Resvick, R. J. Med. Chem. 1991,34, 1879.).
The present invention using the 2'-C- methyl adenines nucleosides with good anticancer and antiviral activity as starting material, A kind of 2'-C- methyl adenines nucleoside phosphoramidites monomer is synthesized, can be as the raw material of RNA nucleotide synthesis in solid state, it can be with One or more 2'-C- methyl adenine nucleoside phosphoramidites monomers, synthesizing new are easily introduced in oligonucleotide fragment Oligonucleotide sequence and its probe.Medicament research and development, base in siRNA (siRNA, small interfering RNA) Because the research of function and the screening etc. in full genome library have broad application prospects.
Invention content
The invention mainly solves the technical problem of providing a kind of 2'-C- methyl adenines nucleoside phosphoramidites monomer and its Synthetic method, the synthesising method reacting condition is mild, and post-processing is simple, easy to operate, is suitble to industrialized production, for a large amount of synthesis Such compound provides condition.Raw material can be provided to synthesize new RNA nucleotide sequences, for novel siRNA medicament research and development and newly Low cost, high speed and the high throughput of nucleic acid sequence analysis technology lay the foundation.
In order to solve the above technical problems, one aspect of the present invention is:Synthesize a kind of 2'-C- methyl adenines Nucleoside phosphoramidites monomer, it is characterised in that structure is:
Wherein R1It is selected from:
R2It is selected from:
R3It is selected from:
R4It is selected from:
Specifically synthesis step is:
(1)Starting material is 2'-C- methyladenosines(2'-C- methyl adenine nucleosides), under alkaline condition, first use two tertiary fourths Base silicon substrate bis- (trifluoromethayl sulfonic acids) protects 5'-OH and 3'-OH to synthesize 1 compound of formula.It then proceedes to that fert-butyidimethylsilyl is added Chlorosilane protects 2'-OH, directly obtains 2 compound of formula;
(2)2 compound of formula, under the action of alkaline condition and catalyst, protection-NH23 compound of synthesis formula, catalyst are preferred DMAP;
(3)3 compound of formula, under the action of alkaline condition and catalyst hydrogen fluoride pyridine, the de- 5'-OH and 3'-OH of selectivity is protected Protect 4 compound of synthesis formula.Then after simple post-processing, directly under the action of alkaline condition and catalyst, selective protection 5'-OH synthesizes 5 compound of formula, protecting group preferably 4,4- dimethoxytrityls, the preferred DMAP of catalyst;
(4)5 compound of formula, under the action of alkaline condition and catalyst, selective protection 3'-OH synthesizes 6 compound of formula.Protection Preferred 2- cyanoethyls N, N- the diisopropyl chloro phosphoramidite of reagent, the preferred DMAP of catalyst.
Raw material of the gained compound of the invention as RNA nucleotide synthesis in solid state, can be easily in oligonucleotide fragment Middle introducing one or more 2'-C- methyl adenine nucleoside phosphoramidites monomers, the oligonucleotide sequence of synthesizing new and its spy Needle.In the medicament research and development of siRNA (siRNA, small interfering RNA), the research of gene function and full genome The screening in library etc. has broad application prospects.
Three kinds of 2'-C- methyl adenine nucleoside phosphoramidites monomers are the priority compounds of the present invention below:
The beneficial effects of the invention are as follows:The present invention is compared with the prior art, have the following advantages that:
1. the great advantage of the present invention is 2'-C- methyl adenine nucleoside phosphoramidites monomers as RNA nucleotide synthesis in solid state Raw material, can easily in oligonucleotide fragment introduce one or more 2'-C- methyl adenine nucleoside phosphoramidites lists Body, the oligonucleotide sequence and its probe of synthesizing new.
2. the synthesising method reacting condition is mild, post-processing is simple, easy to operate, is suitble to industrialized production.
3. the present invention is former using the 2'-C- methyl adenines nucleosides with good anticancer and antiviral activity as starting Material, after thering is the structure of such characteristic to introduce oligonucleotide fragment, in Related Research Domain(Especially siRNA Field of Drug Discovery) It is expected to making a breakthrough property achievement.
4. the starting important source material 2'-C- methyl adenine nucleosides of the present invention, our company has industrialized, of low cost to be easy to get.
Description of the drawings
Fig. 1 is the synthetic route of 2'-C- methyl adenines nucleoside phosphoramidites monomer of the present invention.
Specific implementation mode
The preferred embodiments of the present invention will be described in detail below in conjunction with the accompanying drawings, so that advantages and features of the invention energy It is easier to be readily appreciated by one skilled in the art, so as to make a clearer definition of the protection scope of the present invention.
Referring to Fig. 1, the embodiment of the present invention includes:
Embodiment 1
The synthesis of 3', 5'-O- (di-t-butyl silicon substrate is double) -2'-O- t-butyldimethyl silane -2'-C- methyladenosines:
In 250ml two-mouth bottles, it is separately added into 100mlDMF and 2.8g (10mmol) 2'-C- methyladenosines(This compound our company It has industrialized), under the conditions of nitrogen protection and 0 °C, it is slowly dropped into the bis- (fluoroforms of 4.8g (11mmol) di-t-butyl silicon substrate Sulfonic acid), then it is stirred to react 30 minutes for 0 °C.Then 3.4g (50mmol) imidazoles is added portionwise, is then stirred to react 30 points for 25 °C Clock.1.9g (12mmol) tert-butyl chloro-silicane is slowly added dropwise, is then stirred to react 3 hours for 80 °C.It is cooled to 0 °C of analysis Crystalline substance is filtered and is washed with cold acetonitrile, is finally dried to obtain 4.7g 3', 5'-O- (di-t-butyl silicon substrate is double) -2'-O- tertiary butyls Dimethylsilane -2'-C- methyladenosines, yield 88%.
Embodiment 2
3', 5'-O- (di-t-butyl silicon substrate is double) -2'-O- t-butyldimethyl silane-N6- benzoyl -2'-C- methyladenosines Synthesis:
In 250ml two-mouth bottles, it is separately added into 100ml dichloromethane, 2.7g (5mmol) 3', 5'-O- (di-t-butyl silicon substrate It is double) -2'-O- t-butyldimethyl silane -2'-C- methyladenosines, 1.0g (10mmol) triethylamines and 0.1g (1mmol) DMAP is added dropwise 1.1g (7.5mmol) chlorobenzoyl chloride, is then stirred to react 3 hours for 25 °C under the conditions of nitrogen protection and 0 °C. TLC detections are after the reaction was complete, and water washing is three times(50mlx3), after being dried with anhydrous magnesium sulfate, it is spin-dried for solvent, then uses 20ml second Nitrile is recrystallized to give 2.4g 3', 5'-O- (di-t-butyl silicon substrate is double) -2'-O- t-butyldimethyl silane-N6- benzoyls - 2'-C- methyladenosines, yield 75%.
Embodiment 3
5'-O- (4,4- dimethoxytrityls) -2'-O- [(tertiary butyl) dimethyl silicon substrate]-N6- benzoyl -2'-C- first The synthesis of base adenosine:
In 250ml two-mouth bottles, by 1.3g (2mmol) 3', 5'-O- (di-t-butyl silicon substrate is double) -2'-O- tertiary butyl diformazans Base silane-N6- benzoyl -2'-C- methyladenosines are dissolved in 5Oml anhydrous methylene chlorides.In ice bath and nitrogen protection condition Under, 1.0g (10mmol) hydrogen fluoride pyridine (being dissolved in 6ml pyridines) is slowly added dropwise, after 0 °C of continuation stirring 1 hour, TLC detections After the reaction was complete, 50ml water and 50ml saturated sodium bicarbonate aqueous solutions respectively washed once, and after being dried with anhydrous magnesium sulfate, be spin-dried for molten Agent.Be then respectively adding 50ml dichloromethane, 0.5g (5mmol) triethylamines and 0.03g (0.3mmol) DMAP, in ice bath and Under the conditions of nitrogen protection, 0.7g (2.2mmol) 4,4'- dimethoxytrityl chloride solids are added portionwise, then stir for 25 °C Mix reaction 6 hours.TLC detections are after the reaction was complete, and water washing is three times(50mlx3), after being dried with anhydrous sodium sulfate, it is spin-dried for solvent, Column chromatography (petrol ether/ethyl acetate=3:1) 1.5g 5'-O- (4,4- dimethoxytrityl) -2'-O- [(tertiary fourths, are obtained Base) dimethyl silicon substrate]-N6- benzoyl -2'-C- methyladenosines, yield 93%.
Embodiment 4
5'-O- (4,4- dimethoxytrityls) -2'-O- [(tertiary butyl) dimethyl silicon substrate]-N6- benzoyl -2'-C- first The synthesis of base adenosine -3'- (2- cyano ethyls-N, N- diisopropyl) phosphoramidite:
In 250ml two-mouth bottles, by 1.2g (1.5mmol) 5'-O- (4,4- dimethoxytrityl) -2'-O- [(tertiary fourths Base) dimethyl silicon substrate]-N6- benzoyl -2'-C- methyladenosines are dissolved in 8Oml anhydrous methylene chlorides, then sequentially add The DMAP solids of 0.7g (6mmol) diisopropyl ethyl amines and 0.03g (O.3mmol), under the conditions of ice bath nitrogen protection, slowly 0.7g (3mmol) 2- cyanoethyls N, N- diisopropyl chloro phosphoramidite (being dissolved in 30ml dichloromethane) is added dropwise, continues to stir It mixes after five minutes, restores room temperature, stir 8 hours.TLC detections are after the reaction was complete, after being spin-dried for solvent, direct column chromatography (petroleum ether/ Ethyl acetate=8:1) 1.3g 5'-O- (4,4- dimethoxytrityl) -2'-O- [(tertiary butyl) dimethyl silicon substrate] -, is obtained N6- benzoyl -2'-C- methyladenosines -3'- (2- cyano ethyls-N, N- diisopropyl) phosphoramidite, yield 86%.
Example the above is only the implementation of the present invention is not intended to limit the scope of the invention, every to utilize this hair Equivalent structure or equivalent flow shift made by bright specification and accompanying drawing content is applied directly or indirectly in other relevant skills Art field, is included within the scope of the present invention.

Claims (3)

1. a kind of 2'-C- methyl adenines nucleoside phosphoramidites monomer, it is characterised in that structure is:
Wherein R1It is selected from:
R2It is selected from:
R3It is selected from:
R4It is selected from:
2. a kind of 2'-C- methyl adenines nucleoside phosphoramidites monomer according to claim 1 and its synthetic method, special Sign is that specific synthesis step is:
(1)Starting material is 2'-C- methyladenosines(2'-C- methyl adenine nucleosides), under alkaline condition, first use two tertiary fourths Base silicon substrate bis- (trifluoromethayl sulfonic acids) protects 5'-OH and 3'-OH to synthesize 1 compound of formula;
It then proceedes to that tert-butyl chloro-silicane protection 2'-OH is added, directly obtains 2 compound of formula;
(2)2 compound of formula, under the action of alkaline condition and catalyst, protection-NH23 compound of synthesis formula, catalyst are preferred DMAP;
(3)3 compound of formula, under the action of alkaline condition and catalyst hydrogen fluoride pyridine, the de- 5'-OH and 3'-OH of selectivity is protected 4 compound of synthesis formula is protected, then after simple post-processing, directly under the action of alkaline condition and catalyst, selective protection 5'-OH synthesizes 5 compound of formula, protecting group preferably 4,4- dimethoxytrityls, the preferred DMAP of catalyst;
(4)5 compound of formula, under the action of alkaline condition and catalyst, selective protection 3'-OH synthesizes 6 compound of formula;
Protect preferred 2- cyanoethyls N, N- the diisopropyl chloro phosphoramidite of reagent, the preferred DMAP of catalyst.
3. a kind of 2'-C- methyl adenines nucleoside phosphoramidites monomer according to claim 1 and its synthetic method, special Sign is:Raw material of the 2'-C- methyl adenine nucleoside phosphoramidites monomers as RNA nucleotide synthesis in solid state is (small in siRNA RNA interfering, small interfering RNA) medicament research and development, the research of gene function and the screening etc. in full genome library Application.
CN201810535394.9A 2018-05-30 2018-05-30 A kind of 2`-C- methyl adenines nucleoside phosphoramidites monomer and its synthetic method Pending CN108659080A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201810535394.9A CN108659080A (en) 2018-05-30 2018-05-30 A kind of 2`-C- methyl adenines nucleoside phosphoramidites monomer and its synthetic method

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201810535394.9A CN108659080A (en) 2018-05-30 2018-05-30 A kind of 2`-C- methyl adenines nucleoside phosphoramidites monomer and its synthetic method

Publications (1)

Publication Number Publication Date
CN108659080A true CN108659080A (en) 2018-10-16

Family

ID=63774194

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201810535394.9A Pending CN108659080A (en) 2018-05-30 2018-05-30 A kind of 2`-C- methyl adenines nucleoside phosphoramidites monomer and its synthetic method

Country Status (1)

Country Link
CN (1) CN108659080A (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109970832A (en) * 2019-04-09 2019-07-05 沈阳药科大学 A kind of alkynyl-modified desoxyadenosine phosphoramidite monomer and preparation method thereof
CN114685560A (en) * 2020-12-31 2022-07-01 沈阳药科大学 Synthesis and application of phosphoramidite monomer containing piperidine skeleton and oligonucleotide

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109970832A (en) * 2019-04-09 2019-07-05 沈阳药科大学 A kind of alkynyl-modified desoxyadenosine phosphoramidite monomer and preparation method thereof
CN109970832B (en) * 2019-04-09 2022-06-03 沈阳药科大学 Alkynyl-modified deoxyadenosine phosphoramidite monomer and preparation method thereof
CN114685560A (en) * 2020-12-31 2022-07-01 沈阳药科大学 Synthesis and application of phosphoramidite monomer containing piperidine skeleton and oligonucleotide
CN114685560B (en) * 2020-12-31 2024-05-14 沈阳药科大学 Synthesis and application of phosphoramidite monomer containing piperidine skeleton and oligonucleotide

Similar Documents

Publication Publication Date Title
Langkjær et al. UNA (unlocked nucleic acid): a flexible RNA mimic that allows engineering of nucleic acid duplex stability
Höbartner et al. Chemical synthesis of selenium-modified oligoribonucleotides and their enzymatic ligation leading to an U6 SnRNA stem− loop segment
Büttner et al. Synthesis of spin-labeled riboswitch RNAs using convertible nucleosides and DNA-catalyzed RNA ligation
US9493773B2 (en) Synthesis of deuterated ribo nucleosides, N-protected phosphoramidites, and oligonucleotides
Carrasco et al. Selenium derivatization and crystallization of DNA and RNA oligonucleotides for X‐ray crystallography using multiple anomalous dispersion
AU2011217918A1 (en) Phosphoramidites for synthetic RNA in the reverse direction
Wunderlich et al. Stable isotope-labeled RNA phosphoramidites to facilitate dynamics by NMR
CN108659080A (en) A kind of 2`-C- methyl adenines nucleoside phosphoramidites monomer and its synthetic method
EP2006293B1 (en) 2'-hydroxyl-modified ribonucleoside derivative
Beaucage et al. Recent advances in the chemical synthesis of RNA
CN108659079A (en) 2 '-C- methyl guanosines phosphoramidite monomers of one kind and its synthetic method
US9512162B2 (en) Synthesis of deuterated ribo nucleosides, N-protected phosphoramidites and oligonucleotides
CN108997462A (en) The fluoro- 2`-C- methyl adenine nucleoside phosphoramidites monomer of 2`- deoxidation -2`- and its synthetic method
CN108997460A (en) The fluoro- 2`-C- methyluridine phosphoramidite monomer of 2`- deoxidation -2`- and its synthetic method
US9045521B2 (en) Synthesis of deuterated ribo nucleosides N-protected phosphoramidites, and oligonucleotides
Carlucci et al. Chemical synthesis of LNA-2-thiouridine and its influence on stability and selectivity of oligonucleotide binding to RNA
CN110483604A (en) A kind of 2`-C- methyluridine phosphoramidite monomer and its synthetic method
WO2015137121A1 (en) Ribonucleoside analog having azide groups and method for producing same, and chimera-type oligoribonucleotide analog containing triazole linking-type oligoribonucleotide formed from such analog
CN108948103A (en) The fluoro- 2`-C- methyl guanosine phosphoramidite monomer of 2`- deoxidation -2`- and its synthetic method
Korotkovs et al. Molecular construction of sulfonamide antisense oligonucleotides
AU2012254580B2 (en) Process for preparing phosphate compound bearing isotope
Benckendorff et al. Preparation of a 4′‐Thiouridine Building‐Block for Solid‐Phase Oligonucleotide Synthesis
Zheng et al. Synthesis of N4‐Methylcytidine (m4C) and N4, N4‐Dimethylcytidine (m42C) Modified RNA
Hayashi et al. Syntheses of prodrug-type 2′-O-methyldithiomethyl oligonucleotides modified at natural four nucleoside residues and their conversions into natural 2′-hydroxy oligonucleotides under reducing condition
CN106488926A (en) Compound composition and method comprising heat-labile part

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20181016

WD01 Invention patent application deemed withdrawn after publication